Literature DB >> 8689107

Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer.

M Kriegmair1, R Baumgartner, W Lumper, R Waidelich, A Hofstetter.   

Abstract

OBJECTIVE: To report clinical experience with intravesical instillations of 5-aminolevulinic acid (ALA) for the photodynamic therapy of superficial bladder cancer and to assess any side-effects of the treatment. PATIENTS AND METHODS: Ten patients (six men and four women, mean age 62.3 years, range 42-73) with refractory superficial bladder cancer were treated with photodynamic therapy using 5 g of ALA dissolved in 30 mL sodium bicarbonate instilled intravesically. After a mean retention of 5.1 h, the bladder interior was illuminated transurethrally at radiation integrals of 15, 30 or 60 J/cm2. At integrals of 15 or 30 J/cm2 red light (635 nm) was used and at 60 J/cm2, green light (514 nm, 40 J/cm2) was combined with a subsequent application of red light (635 nm, 20 J/cm2).
RESULTS: After 10-12 weeks, four patients had a complete remission, two a partial remission, there was no change in three and one had progressive disease. Of those patients responding, the bladder was preserved in five after a mean follow-up of 15 months (range 6-27). There were no photodermatoses or bladder shrinkage in any patient.
CONCLUSIONS: Photodynamic therapy with intravesically applied ALA is effective in destroying superficial urothelial carcinomas of the bladder. There were no serious side-effects which could preclude further clinical testing.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8689107     DOI: 10.1046/j.1464-410x.1996.09717.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  12 in total

Review 1.  Photodynamic therapy.

Authors:  D C Shackley; C Whitehurst; N W Clarke; C Betts; J V Moore
Journal:  J R Soc Med       Date:  1999-11       Impact factor: 5.344

Review 2.  A review of progress in clinical photodynamic therapy.

Authors:  Z Huang
Journal:  Technol Cancer Res Treat       Date:  2005-06

3.  Photodynamic therapy with ATX-S10.Na(II) inhibits synovial sarcoma cell growth.

Authors:  Ken Takeda; Toshiyuki Kunisada; Shinichi Miyazawa; Yoshinori Nakae; Toshifumi Ozaki
Journal:  Clin Orthop Relat Res       Date:  2008-05-09       Impact factor: 4.176

4.  Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line.

Authors:  S N Datta; R Allman; C Loh; M Mason; P N Matthews
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study.

Authors:  N Lange; P Jichlinski; M Zellweger; M Forrer; A Marti; L Guillou; P Kucera; G Wagnières; H van den Bergh
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

Review 6.  Immunotherapy for bladder cancer.

Authors:  Oliver Fuge; Nikhil Vasdev; Paula Allchorne; James Sa Green
Journal:  Res Rep Urol       Date:  2015-05-04

Review 7.  The Dark Side: Photosensitizer Prodrugs.

Authors:  Sara Sansaloni-Pastor; Jordan Bouilloux; Norbert Lange
Journal:  Pharmaceuticals (Basel)       Date:  2019-10-04

8.  The influence of hypoxia and pH on aminolaevulinic acid-induced photodynamic therapy in bladder cancer cells in vitro.

Authors:  L Wyld; M W Reed; N J Brown
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

9.  Quantitative studies of the kinetics of 5-aminolaevulinic acid-induced fluorescence in bladder transitional cell carcinoma.

Authors:  S N Datta; C S Loh; A J MacRobert; S D Whatley; P N Matthews
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

10.  Cell cycle phase influences tumour cell sensitivity to aminolaevulinic acid-induced photodynamic therapy in vitro.

Authors:  L Wyld; O Smith; J Lawry; M W Reed; N J Brown
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.